Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228579 | 0.81 | POLB (0.52) | POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8223026 | 0.81 | POLB (0.52) | POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13360003 | 0.81 | POLB (0.52) | POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10174373 | 0.78 | SMN1; SMN2 (0.43) | POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL694533 | 0.78 | POLB (0.41) | POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13131163 | 0.78 | POLB (0.38) | POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL877644 | 0.78 | KDM4E (0.41) | POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL4503380 | 0.78 | POLB (0.41) | POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4493171 | 0.78 | POLB (0.38) | POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3971854 | 0.78 | SMN1; SMN2 (0.41) | POLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553842-B2 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | ARRAY BIOPHARMA INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1838316-A2 | MACROCYCLIC ANALOGS FOR THE TREATMENT OF IMMUNOREGULATORY DISORDERS AND RESPIRATORY DISEASES | Array Biopharma, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006078724-A2 | MACROCYCLIC ANALOGS FOR THE TREATMENT OF IMMUNOREGULATORY DISORDERS AND RESPIRATORY DISEASES | ARRAY BIOPHARMA NC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160838-A1 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | ARRAY BIOPHARMA INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160838-A1 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | TSLP, XDH, IFNG | POLB 2107/4885TDP1 2913/4885CES2 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.